Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-2006 is a long-acting, sustained-release injectable formulation of bupivacaine being developed by G2G Bio for the management of post-operative pain in veterinary medicine. The drug utilizes G2G Bio's proprietary InnoLamp (Innovative Long-Acting MicroParticle) technology, which encapsulates the local anesthetic within biodegradable PLGA (poly lactic-co-glycolic acid) microparticles. This formulation is designed to provide a controlled, extended release of bupivacaine at the surgical site, offering prolonged local analgesia and reducing the need for systemic pain management, such as opioids, in animals following surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GB-2006.